»  Please click here to follow the SMIR news and events
  e-Learning In RCPN (eLIR)
 »  Please click here to follow the e-Learning In RCPN (eLIR)
 » Research Center for Pharmaceutical Nanotechnology, Research and Development Complex, Tabriz University of Medical Sciences, Daneshgah street, Tabriz, IRAN. Postal Code: 5165665811

T +98 (41) 33367914
F +98 (41) 33367929  

  Protein-based nanobiomaterials: Antibodies, vaccine and enzymes


Technical approach

Research leader

Research assistants

Post-doc researchers


Selected publications


Protein- based nanomaterials : Antibodies, vaccine and enzymes

The mission of the laboratory is to bridge the gap between nanotechnology and molecular medicine researches, translating novel discoveries into cutting-edge tests and accelerating the translation of nanomedicine discoveries into cancer therapy. The main research programs of this laboratory are on nanobiosensing focused on cancer diagnosis areas. Biosensor technology is probably one of the fastest growing areas to early detection of cancers. As aptamers show high target affinity and high target specificity, they can be used as therapeutic agents, in affinity columns and as recognition elements in sensors detecting a wide range of targets. Then, our group focused to designing of aptamers and apobody-based optical and electrochemical biosensors to cancer detection. The SELEX process that is a technique for screening a very large library of oligonucleotides with random sequences by iterative cycles of selection and amplification has been used in our laboratory.

Technical approach


DNA cloning

Genetic manipulation of bacteria, microalgae & yeast

Aptamer designingApo-body designing

Phag display Technology

Cancer biomarker discovering




Research Leader

Dr. Mohammad Reza Tohidkia, (M.Sc, PhD)
Dr. Mohammad Mostafa Pourseif, (M.Sc, PhD)
Dr.Azam Safary, (M.Sc, PhD)
Dr. Ali mesghary shadi, (M.Sc, PhD)

Dr.Jaber  dehghani,(M.Sc,PhD)
Prof. Yadollah Omidi, (PharmD, Ph.D)


Research Assistants

Rahimeh Mousavi



Post-doc Researchers


Jaber Dehghani received his B.S. degree in plant biology in 2008 from Zabol University and his M.S degree in plant developmental cell biology in 2012 from Tabriz University (the one of best university in Iran). Immediately, he started Ph.D. studying in plant cellular and molecular biology in University of Tabriz, as a top student in the entrance exam of universities. Presently, he focused on molecular identification of micro-algae and production of recombinant proteins.


PhD Students

Hadi Maleki Kakelar obtained his BSc in Biology in 2007 and MSc in Microbiology in 2010 from Islamic Azad University of Zanjan. His major is cellular/molecular biology. He started his Ph.D. in nanobiomedicine in Tabriz University of Medical Sciences (TUOMS), Tabriz, Iran in 2014. Hadi is greatly dedicated to his work, and possesses unparalleled ability in research activities which make him a significant researcher. He meets deadlines and conducts pure research. His creative mind and curiosity paves his way for future achievements and successes.
Somayeh Vandghanooni received M.Sc (2007) of genetics and B.Sc of biology (2005) from the department of biology-genetic of Tabriz University. Her M.Sc project was about studying survivin gene expression and its splice variants as diagnostic biomarkers for malignant papillary thyroid tumors.  She was a member of exceptional talent organization during her education in both courses at university of Tabriz. She started her PhD in nanobiotechnology (2014) at Research Center for Pharmaceutical Nanotechnology (RCPN), Tabriz University of Medical Sciences, Tabriz, Iran. Her PhD thesis is about the engineering of targeted drug delivery nanomachinery system for ovarian cancer chemo/gene therapy which is in progress under the supervision of Prof. Y. Omidi and Prof. J. Barar and advising of Dr. Eskandani.  








Selected Publication based on scopus

Last two years publications (2017-2018)



1.         Fahimi F, Sarhaddi S, Fouladi M, Samadi N, Sadeghi J, Golchin A, et al. Phage display-derived antibody fragments against conserved regions of VacA toxin of Helicobacter pylori. Applied Microbiology and Biotechnology. 2018;102(16):6899-913.

2.         Fahimi F, Tohidkia MR, Fouladi M, Aqabeigi R, Samadi N, Omidi Y. Pleiotropic cytotoxicity of VacA toxin in host cells and its impact on immunotherapy. BioImpacts. 2017;7(1):59-71.

3.         Gharaati-Far N, Tohidkia MR, Dehnad A, Omidi Y. Efficiency and cytotoxicity analysis of cationic lipids-mediated gene transfection into AGS gastric cancer cells. Artificial Cells, Nanomedicine and Biotechnology. 2018;46(5):1001-8.

4.         Khajeh S, Tohidkia MR, Aghanejad A, Mehdipour T, Fathi F, Omidi Y. Phage display selection of fully human antibody fragments to inhibit growth-promoting effects of glycine-extended gastrin 17 on human colorectal cancer cells. Artificial Cells, Nanomedicine and Biotechnology. 2018:1-9.

5.         Tohidkia MR, Sepehri M, Khajeh S, Barar J, Omidi Y. Improved Soluble ScFv ELISA Screening Approach for Antibody Discovery Using Phage Display Technology. SLAS Discovery. 2017;22(8):1026-34.

6.         Asgharzadeh MR, Barar J, Pourseif MM, Eskandani M, Niya MJ, Mashayekhi MR, et al. Molecular machineries of pH dysregulation in tumor microenvironment: Potential targets for cancer therapy. BioImpacts. 2017;7(2):115-33.

7.         Dehghani J, Adibkia K, Movafeghi A, Barzegari A, Pourseif MM, Maleki Kakelar H, et al. Stable transformation of Spirulina (Arthrospira) platensis: a promising microalga for production of edible vaccines. Applied Microbiology and Biotechnology. 2018;102(21):9267-78.

8.         Pourseif MM, Moghaddam G, Daghighkia H, Nematollahi A, Omidi Y. A novel B- and helper T-cell epitopes-based prophylactic vaccine against Echinococcus granulosus. BioImpacts. 2018;8(1):39-52.

9.         Pourseif MM, Moghaddam G, Naghili B, Saeedi N, Parvizpour S, Nematollahi A, et al. A novel in silico minigene vaccine based on CD4+ T-helper and B-cell epitopes of EG95 isolates for vaccination against cystic echinococcosis. Computational Biology and Chemistry. 2018;72:150-63.

10.       Pourseif MM, Moghaddam G, Saeedi N, Barzegari A, Dehghani J, Omidi Y. Current status and future prospective of vaccine development against Echinococcus granulosus. Biologicals : journal of the International Association of Biological Standardization. 2018;51:1-11.

11.       Safary A, Khiavi MA, Mousavi R, Barar J, Rafi MA. Enzyme replacement therapies: What is the best option? BioImpacts. 2018;8(3):153-7.

12.       Abdollahi-Aghdam A, Majidi MR, Omidi Y. Microfluidic paper-based analytical devices (µPADs) for fast and ultrasensitive sensing of biomarkers and monitoring of diseases. BioImpacts. 2018;8(4):237-40.

13.       Aghanejad A, Babamiri H, Adibkia K, Barar J, Omidi Y. Mucin-1 aptamer-armed superparamagnetic iron oxide nanoparticles for targeted delivery of doxorubicin to breast cancer cells. BioImpacts. 2018;8(2):117-27.

14.       Akbari Nakhjavani S, Khalilzadeh B, Samadi Pakchin P, Saber R, Ghahremani MH, Omidi Y. A highly sensitive and reliable detection of CA15-3 in patient plasma with electrochemical biosensor labeled with magnetic beads. Biosensors and Bioelectronics. 2018;122:8-15.

15.       Arteshi Y, Aghanejad A, Davaran S, Omidi Y. Biocompatible and electroconductive polyaniline-based biomaterials for electrical stimulation. European Polymer Journal. 2018;108:150-70.

16.       Asghari S, Movafeghi A, Lisar SYS, Barar J, Omidi Y. Effects of phenanthrene on growth parameters and antioxidant systems in the green microalga chlorella vulgaris. Biointerface Research in Applied Chemistry. 2018;8(4):3405-11.

17.       Asoudeh-Fard A, Barzegari A, Dehnad A, Bastani S, Golchin A, Omidi Y. Lactobacillus plantarum induces apoptosis in oral cancer KB cells through upregulation of PTEN and downregulation of MAPK signaling pathways. BioImpacts. 2017;7(3):193-8.

18.       Bakhtiary Z, Barar J, Aghanejad A, Saei AA, Nemati E, Ezzati Nazhad Dolatabadi J, et al. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer. Drug Development and Industrial Pharmacy. 2017;43(8):1244-53.

19.       Borran AA, Aghanejad A, Farajollahi A, Barar J, Omidi Y. Gold nanoparticles for radiosensitizing and imaging of cancer cells. Radiation Physics and Chemistry. 2018;152:137-44.

20.       Daryanoosh M, Goudarzi G, Rashidi R, Keishams F, Hopke PK, Mohammadi MJ, et al. Risk of morbidity attributed to ambient PM<inf>10</inf>in the western cities of Iran. Toxin Reviews. 2017:1-6.

21.       Eskandani M, Vandghanooni S, Barar J, Nazemiyeh H, Omidi Y. Cell physiology regulation by hypoxia inducible factor-1: Targeting oxygen-related nanomachineries of hypoxic cells. International Journal of Biological Macromolecules. 2017;99:46-62.

22.       Fathi M, Majidi S, Zangabad PS, Barar J, Erfan-Niya H, Omidi Y. Chitosan-based multifunctional nanomedicines and theranostics for targeted therapy of cancer. Medicinal Research Reviews. 2018;38(6):2110-36.

23.       Fathi M, Sahandi Zangabad P, Barar J, Aghanejad A, Erfan-Niya H, Omidi Y. Thermo-sensitive chitosan copolymer-gold hybrid nanoparticles as a nanocarrier for delivery of erlotinib. International Journal of Biological Macromolecules. 2018;106:266-76.

24.       Fathi M, Zangabad PS, Aghanejad A, Barar J, Erfan-Niya H, Omidi Y. Folate-conjugated thermosensitive O-maleoyl modified chitosan micellar nanoparticles for targeted delivery of erlotinib. Carbohydrate Polymers. 2017;172:130-41.

25.       Fathi M, Zangabad PS, Majidi S, Barar J, Erfan-Niya H, Omidi Y. Stimuli-responsive chitosan-based nanocarriers for cancer therapy. BioImpacts. 2017;7(4):269-77.

26.       Ferdousi R, Safdari R, Omidi Y. Computational prediction of drug-drug interactions based on drugs functional similarities. Journal of Biomedical Informatics. 2017;70:54-64.

27.       Goudarzi G, Daryanoosh SM, Godini H, Hopke PK, Sicard P, De Marco A, et al. Health risk assessment of exposure to the Middle-Eastern Dust storms in the Iranian megacity of Kermanshah. Public Health. 2017;148:109-16.

28.       Jafarizad A, Aghanejad A, Sevim M, Metin Ö, Barar J, Omidi Y, et al. Gold Nanoparticles and Reduced Graphene Oxide-Gold Nanoparticle Composite Materials as Covalent Drug Delivery Systems for Breast Cancer Treatment. ChemistrySelect. 2017;2(23):6663-72.

29.       Karami P, Majidi MR, Johari-Ahar M, Barar J, Omidi Y. Development of screen-printed tryptophan-kynurenine immunosensor for in vitro assay of kynurenine-mediated immunosuppression effect of cancer cells on activated T-cells. Biosensors and Bioelectronics. 2017;92:287-93.

30.       Maleki Kakelar H, Barzegari A, Dehghani J, Hanifian S, Saeedi N, Barar J, et al. Pathogenicity of Helicobacter pylori in cancer development and impacts of vaccination. Gastric Cancer. 2018.

31.       Mesgari-Shadi A, Sarrafzadeh MH, Barar J, Omidi Y. Cost-effective batch production process of scFv antibody in Escherichia coli. Human Antibodies. 2017;26(3):149-57.

32.       Mesgari-Shadi A, Sarrafzadeh MH, Divband B, Barar J, Omidi Y. Batch adsorption/desorption for purification of scFv antibodies using nanozeolite microspheres. Microporous and Mesoporous Materials. 2018;264:167-75.

33.       Mohammadi MJ, Yari AR, Saghazadeh M, Sobhanardakani S, Geravandi S, Afkar A, et al. A health risk assessment of heavy metals in people consuming Sohan in Qom, Iran. Toxin Reviews. 2017:1-9.

34.       Momtazan M, Geravandi S, Rastegarimehr B, Valipour A, Ranjbarzadeh A, Yari AR, et al. An investigation of particulate matter and relevant cardiovascular risks in Abadan and Khorramshahr in 2014–2016. Toxin Reviews. 2018:1-8.

35.       Nakhlband A, Eskandani M, Omidi Y, Saeedi N, Ghaffari S, Barar J, et al. Combating atherosclerosis with targeted nanomedicines: Recent advances and future prospective. BioImpacts. 2018;8(1):59-75.

36.       Nakhlband A, Eskandani M, Saeedi N, Ghafari S, Omidi Y, Barar J, et al. Marrubiin-loaded solid lipid nanoparticles’ impact on TNF-α treated umbilical vein endothelial cells: A study for cardioprotective effect. Colloids and Surfaces B: Biointerfaces. 2018;164:299-307.

37.       Neisi A, Albooghobeish M, Geravandi S, Adeli Behrooz HR, Mahboubi M, Omidi Khaniabad Y, et al. Investigation of health risk assessment sevoflurane on indoor air quality in the operation room in Ahvaz city, Iran. Toxin Reviews. 2018:1-9.

38.       Neisi A, Idani E, Vosoughi M, Hazrati S, Babaei AA, Takdastan A, et al. Answers to the comments on “Air pollution, biological marker and lung function in children”. Environmental Science and Pollution Research. 2018;25(27):27669-71.

39.       Nemati E, Azami A, Mokhtarzadeh A, Rahbar Saadat Y, Omidi Y, Ezzati Nazhad Dolatabadi J. Formulation and characterization of ethambutol loaded nanostructured lipid carrier. Latin American Journal of Pharmacy. 2017;36(2):247-52.

40.       Omidi Khaniabadi Y, Sicard P, Omidi Khaniabadi A, Mohammadinejad S, Keishams F, Takdastan A, et al. Air quality modeling for health risk assessment of ambient PM<inf>10</inf>, PM<inf>2.5</inf> and SO<inf>2</inf> in Iran. Human and Ecological Risk Assessment. 2018.

41.       Pakchin PS, Nakhjavani SA, Saber R, Ghanbari H, Omidi Y. Recent advances in simultaneous electrochemical multi-analyte sensing platforms. TrAC - Trends in Analytical Chemistry. 2017;92:32-41.

42.       Panahpour H, Farhoudi M, Omidi Y, Mahmoudi J. An in vivo assessment of blood-brain barrier disruption in a rat model of ischemic stroke. Journal of Visualized Experiments. 2018;2018(133).

43.       Parvizpour S, Razmara J, Omidi Y. Breast cancer vaccination comes to age: Impacts of bioinformatics. BioImpacts. 2018;8(3):223-35.

44.       Rahmanian N, Eskandani M, Barar J, Omidi Y. Recent trends in targeted therapy of cancer using graphene oxide-modified multifunctional nanomedicines. Journal of Drug Targeting. 2017;25(3):202-15.

45.       Ranjbar-Navazi Z, Eskandani M, Johari-Ahar M, Nemati A, Akbari H, Davaran S, et al. Doxorubicin-conjugated D-glucosamine- and folate- bi-functionalised InP/ZnS quantum dots for cancer cells imaging and therapy. Journal of Drug Targeting. 2018;26(3):267-77.

46.       Rodriguez-Ruiz V, Salatti-Dorado JÁ, Barzegari A, Nicolas-Boluda A, Houaoui A, Caballo C, et al. Astaxanthin-loaded nanostructured lipid carriers for preservation of antioxidant activity. Molecules. 2018;23(10).

47.       Salmanzadeh R, Eskandani M, Mokhtarzadeh A, Vandghanooni S, Ilghami R, Maleki H, et al. Propyl gallate (PG) and tert-butylhydroquinone (TBHQ) may alter the potential anti-cancer behavior of probiotics. Food Bioscience. 2018;24:37-45.

48.       Samadi Pakchin P, Ghanbari H, Saber R, Omidi Y. Electrochemical immunosensor based on chitosan-gold nanoparticle/carbon nanotube as a platform and lactate oxidase as a label for detection of CA125 oncomarker. Biosensors and Bioelectronics. 2018;122:68-74.

49.       Shakoori Z, Ghanbari H, Omidi Y, Pashaiasl M, Akbarzadeh A, Jomeh Farsangi Z, et al. Fluorescent multi-responsive cross-linked P(N-isopropylacrylamide)-based nanocomposites for cisplatin delivery. Drug Development and Industrial Pharmacy. 2017;43(8):1283-91.

50.       Vandghanooni S, Eskandani M, Barar J, Omidi Y. AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells. Nanomedicine. 2018;13(21).

51.       Vandghanooni S, Eskandani M, Barar J, Omidi Y. Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective. Journal of Molecular Medicine. 2018;96(9):885-902.

52.       Vandghanooni S, Eskandani M, Barar J, Omidi Y. Recent advances in aptamer-armed multimodal theranostic nanosystems for imaging and targeted therapy of cancer. European Journal of Pharmaceutical Sciences. 2018;117:301-12.

53.       Zamanlu M, Farhoudi M, Eskandani M, Mahmoudi J, Barar J, Rafi M, et al. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke. Journal of Drug Targeting. 2018;26(2):95-109.

54.       Zeydouni G, Kianizadeh M, Omidi Khaniabadi Y, Nourmoradi H, Esmaeili S, Mohammadi MJ, et al. Eriochrme black-T removal from aqueous environment by surfactant modified clay: equilibrium, kinetic, isotherm, and thermodynamic studies. Toxin Reviews. 2018:1-11.

55.       Zeydouni G, Rodriguez Couto S, Nourmoradi H, Basiri H, Amoatey P, Esmaeili S, et al. H<inf>2</inf>SO<inf>4</inf>-modified Aloe vera leaf shells for the removal of P-chlorophenol and methylene blue from aqueous environment. Toxin Reviews. 2018:1-11.

56.       Zununi Vahed S, Barzegari A, Rahbar Saadat Y, Goreyshi A, Omidi Y. Leuconostoc mesenteroides-derived anticancer pharmaceuticals hinder inflammation and cell survival in colon cancer cells by modulating NF-κB/AKT/PTEN/MAPK pathways. Biomedicine and Pharmacotherapy. 2017;94:1094-100.

57.       Zununi Vahed S, Moghaddas Sani H, Rahbar Saadat Y, Barzegari A, Omidi Y. Type 1 diabetes: Through the lens of human genome and metagenome interplay. Biomedicine and Pharmacotherapy. 2018;104:332-42.

58.       Zununi Vahed S, Omidi Y, Ardalan M, Samadi N. Dysregulation of urinary miR-21 and miR-200b associated with interstitial fibrosis and tubular atrophy (IFTA) in renal transplant recipients. Clinical Biochemistry. 2017;50(1-2):32-9.

59.       Zununi Vahed S, Poursadegh Zonouzi A, Ghanbarian H, Ghojazadeh M, Samadi N, Omidi Y, et al. Differential expression of circulating miR-21, miR-142-3p and miR-155 in renal transplant recipients with impaired graft function. International Urology and Nephrology. 2017;49(9):1681-9.

60.       Zununi Vahed S, Poursadegh Zonouzi A, Mahmoodpoor F, Samadi N, Ardalan M, Omidi Y. Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction. Archives of Medical Research. 2017;48(1):96-104.